FI973259A - LCK-SH2-spesifisten yhdisteiden käyttö hoidettaessa autoimmuunisairauksia ja kudossiirrännäisten hyljintää - Google Patents

LCK-SH2-spesifisten yhdisteiden käyttö hoidettaessa autoimmuunisairauksia ja kudossiirrännäisten hyljintää Download PDF

Info

Publication number
FI973259A
FI973259A FI973259A FI973259A FI973259A FI 973259 A FI973259 A FI 973259A FI 973259 A FI973259 A FI 973259A FI 973259 A FI973259 A FI 973259A FI 973259 A FI973259 A FI 973259A
Authority
FI
Finland
Prior art keywords
lck
treatment
autoimmune diseases
transplant rejection
specific compounds
Prior art date
Application number
FI973259A
Other languages
English (en)
Swedish (sv)
Other versions
FI973259A0 (fi
Inventor
Damien J Dunnington
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of FI973259A0 publication Critical patent/FI973259A0/fi
Publication of FI973259A publication Critical patent/FI973259A/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI973259A 1995-02-10 1997-08-07 LCK-SH2-spesifisten yhdisteiden käyttö hoidettaessa autoimmuunisairauksia ja kudossiirrännäisten hyljintää FI973259A (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38638195A 1995-02-10 1995-02-10
US40022095A 1995-03-07 1995-03-07
US49735795A 1995-06-30 1995-06-30
PCT/US1996/001964 WO1996024343A1 (en) 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Publications (2)

Publication Number Publication Date
FI973259A0 FI973259A0 (fi) 1997-08-07
FI973259A true FI973259A (fi) 1997-10-08

Family

ID=27409758

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973259A FI973259A (fi) 1995-02-10 1997-08-07 LCK-SH2-spesifisten yhdisteiden käyttö hoidettaessa autoimmuunisairauksia ja kudossiirrännäisten hyljintää

Country Status (10)

Country Link
EP (2) EP0809490A4 (fi)
JP (2) JPH10513474A (fi)
KR (1) KR19980702115A (fi)
AU (1) AU4923796A (fi)
BR (1) BR9607614A (fi)
CA (1) CA2212645A1 (fi)
FI (1) FI973259A (fi)
HU (1) HUP9802078A3 (fi)
NO (1) NO973659L (fi)
WO (1) WO1996024343A1 (fi)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
WO2005090317A1 (en) 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes

Also Published As

Publication number Publication date
HUP9802078A3 (en) 1999-04-28
CA2212645A1 (en) 1996-08-15
NO973659L (no) 1997-10-08
FI973259A0 (fi) 1997-08-07
HUP9802078A2 (hu) 1998-12-28
JPH10513474A (ja) 1998-12-22
EP0809490A4 (en) 1999-10-20
EP0809490A1 (en) 1997-12-03
BR9607614A (pt) 1998-06-09
JPH10513564A (ja) 1998-12-22
EP0811159A1 (en) 1997-12-10
WO1996024343A1 (en) 1996-08-15
AU4923796A (en) 1996-08-27
KR19980702115A (ko) 1998-07-15
NO973659D0 (no) 1997-08-08

Similar Documents

Publication Publication Date Title
DE69117117D1 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
ID17156A (id) Zat-zat anti koagulan yang berguna dalam pengobatan trombosis
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
DE69505657D1 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE59207750D1 (de) Wegwerfhöschen und Verfahren zur Herstellung desselben
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69600100D1 (de) Puderquaste zur örtlichen Behandlung der Haut
BR9406209A (pt) Derivados heterociclicos no tratamento de isquemia e doenças relacionadas
DE69635364D1 (de) Blutfilter und extrakorporaler Kreislauf
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
FI952656A0 (fi) Foerfarande och anordning vid pulsmaetning av en person
FI965204A (fi) Bromelaiinin lääkekäyttö
ATE225662T1 (de) Verwendung von unverdaulichen oligosacchariden zur vorbeugung und behandlung von mittelohrentzündung bei menschen
ID21948A (id) Penggunaan 1-hidroksi-2piridon untuk pengobatan infeksi-infeksi kulit
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
FI955786A (fi) Luonnontuotteiden ja vastaavien yhdisteiden käyttö sydän- ja verisuonisairauksien hoitoon
FR2751541B1 (fr) Composition dermo-cosmetique contenant un alcaloide du quinquina et methode de traitement cosmetique de l'alopecie
FI941345A (fi) Retinoidit ja niiden käyttö ihosairauksien ja leukemian hoitoon
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69822276T2 (de) Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
FI973259A (fi) LCK-SH2-spesifisten yhdisteiden käyttö hoidettaessa autoimmuunisairauksia ja kudossiirrännäisten hyljintää
ZA971607B (en) Methods of treatment of allergic diseases